Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 5 for:    CLEAR Outcomes bempedoic acid
Previous Study | Return to List | Next Study

Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02993406
Recruitment Status : Active, not recruiting
First Posted : December 15, 2016
Last Update Posted : September 14, 2021
The Cleveland Clinic
Information provided by (Responsible Party):
Esperion Therapeutics, Inc.

Brief Summary:
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Statin Adverse Reaction Drug: Bempedoic acid 180 mg tablet Drug: Matching placebo tablet Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14014 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant
Actual Study Start Date : November 18, 2016
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Bempedoic Acid 180 mg
Bempedoic acid 180 mg tablet taken orally, once daily.
Drug: Bempedoic acid 180 mg tablet
Patients take bempedoic acid 180 mg tablet orally once daily
Other Name: ETC-1002

Placebo Comparator: Placebo Comparator
Matching placebo tablet taken orally, once daily
Drug: Matching placebo tablet
Patients take matching placebo tablet orally once daily
Other Name: placebo comparator

Primary Outcome Measures :
  1. Time from randomization to first occurrence of one of the following adjudicated composite endpoints: CV death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization. [ Time Frame: 3.75 years (estimated average treatment duration) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 18 and 85 years
  • History of, or at high risk for, cardiovascular disease (CVD) including coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease, or at high risk for a cardiovascular event
  • Patient reported history of statin intolerance (inability to tolerate 2 or more statins, one at a low dose)
  • Men and nonpregnant, nonlactating women
  • Fasting blood LDL-cholesterol ≥ 100 (2.6 mmol/L) at screening

Exclusion Criteria:

  • Fasting blood triglycerides greater than 500 mg/dL (5.6 mmol/L) at screening
  • Recent (within 90 days of screening) history of major cardiovascular events, transient ischemic attack (TIA), or unstable or symptomatic cardiac arrhythmia
  • History of severe heart failure
  • Uncontrolled hypertension or uncontrolled diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02993406

Show Show 1360 study locations
Sponsors and Collaborators
Esperion Therapeutics, Inc.
The Cleveland Clinic
Layout table for investigator information
Study Director: Michael Louie, MD Esperion Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Esperion Therapeutics, Inc. Identifier: NCT02993406    
Other Study ID Numbers: 1002-043
First Posted: December 15, 2016    Key Record Dates
Last Update Posted: September 14, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Enzyme Inhibitors
Hypoglycemic Agents
Physiological Effects of Drugs